FTRE
FTRE clinical trials: Fortrea Holdings Inc.
Every trial on ClinicalTrials.gov where Fortrea Holdings Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 34
- Trials linked
- 0
- As lead sponsor
- 34
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
FTRE on the catalyst calendar · FTRE registry changes
- Primary completion Oct 11, 2028Sponsor estimatePhase 1/Phase 2NCT07109219Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaAstraZeneca · B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06713369AZD5305 hADME in Patients With Advanced Solid MalignanciesAstraZeneca · Locally Advanced or Metastatic Solid TumorRecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2027Sponsor estimatePhase 3NCT06706817A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment...AstraZeneca · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 19, 2026ActualPhase 1NCT06398730A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of...GE Healthcare · Healthy VolunteersCompletedFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2026Sponsor estimatePhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2026ActualPhase 1NCT07754331Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/DapagliflozinAstraZeneca · Kidney FailureCompletedAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2027Sponsor estimatePhase 1NCT06916806A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus...AstraZeneca · Systemic Lupus ErythematosusRecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 2NCT07884136RBD1119 in Coronary Artery Disease (CAD)Ribocure Pharmaceuticals AB · Stable Coronary Artery DiseaseNot yet recruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 25, 2027Sponsor estimatePhase 3NCT06473779Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With...AstraZeneca · Severe AsthmaActive, not recruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2025ActualNo phase registeredNCT04498026Adherus™ Dural Sealant in Spinal ProceduresStryker Craniomaxillofacial · Spinal DuraplastyCompletedFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 2NCT07850453Vortosiran for VTE PreventionRibocure Pharmaceuticals AB · Venous Thromboembolism (VTE)Not yet recruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2032Sponsor estimatePhase 4NCT06651970Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureAstraZeneca · Chronic Lymphocytic LeukaemiaRecruitingAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 3NCT05933057Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyItalfarmaco · Duchenne Muscular DystrophyRecruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2030Sponsor estimatePhase 3NCT07516132Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular...Ocular Therapeutix, Inc. · Neovascular Age-Related Macular Degeneration (nAMD)RecruitingOCULLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 2/Phase 3NCT07219238Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal...GE Healthcare · Colorectal CancerRecruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 9, 2028Sponsor estimatePhase 3NCT05693129Pediatric Patients Aged 1 to 6 Years With APDSPharming Technologies B.V. · APDSActive, not recruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 3NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSPharming Technologies B.V. · APDSActive, not recruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2025ActualPhase 1NCT07093398A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult ParticipantsD3 Bio (Wuxi) Co., Ltd · Healthy Adult VolunteersCompletedFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07017933Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes3ive Labs · Renal Impairment After Cardiac SurgeryRecruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2026ActualPhase 4NCT06563102Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as...AstraZeneca · Mild AsthmaCompletedAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2025ActualPhase 2NCT06692764A Study to Assess the Effect of AZD0780 on Ambulatory Blood PressureAstraZeneca · Atherosclerotic Cardiovascular DiseaseCompletedAZNLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 20, 2026Sponsor estimatePhase 3NCT06933472A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaAlebund Pharmaceuticals · HyperphosphatemiaRecruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2027Sponsor estimateNo phase registeredNCT06083012Clinical and Healthcare Economic OutcoMes From ReAl-worlD Use in Europe of an AI Software During AF AblationVolta Medical · Atrial FibrillationActive, not recruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 1/Phase 2NCT07244705A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRCAnbogen Therapeutics, Inc. · Colorectal Cancer (Diagnosis)RecruitingFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2023ActualNo phase registeredNCT04702451Tailored vs. Anatomical Ablation Strategy for Persistent Atrial FibrillationVolta Medical · Atrial FibrillationCompletedFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 9 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner